[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355826-105":59,"doc-detail-355826-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","claudin182-positive-gastric-cancer-biology-tumor-microenvironment-and-therapeutic-strategies","Claudin18.2 positive gastric cancer - biology, tumor microenvironment, and therapeutic strategies","","Claudin18.2 (CLDN18.2) is expressed in gastric epithelial cells and is essential for maintaining the integrity of the gastric mucosal barrier. Aberrant CLDN18.2 expression is linked to gastric cancer initiation, progression, and remodeling of the tumor microenvironment (TME), and occurs in a substantial proportion of cases. Its expression is largely independent of established biomarkers such as HER2 and PD-L1. CLDN18.2 positivity correlates with prognosis and suggests a distinctive TME with increased CD4+ and CD8+ T-cell infiltration, macrophages, and cancer-associated fibroblasts. This review summarizes CLDN18.2 biology, associated TME features, and emerging therapeutic strategies to support future precision treatment optimization.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/claudin182-positive-gastric-cancer-biology-tumor-microenvironment-and-therapeutic-strategies/355826/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/claudin182-positive-gastric-cancer-biology-tumor-microenvironment-and-therapeutic-strategies/355826.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does Claudin18.2 play in the gastric mucosal barrier?","Question",{"text":112,"@type":113},"Claudin18.2 is primarily expressed in gastric epithelial cells and contributes crucially to maintaining the integrity of the gastric mucosal barrier.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is Claudin18.2 expression related to established biomarkers like HER2 and PD-L1?",{"text":117,"@type":113},"CLDN18.2 expression is described as largely independent of established biomarkers such as HER2 and PD-L1, suggesting it can provide distinct clinical information.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is Claudin18.2 considered a therapeutic target in gastric cancer?",{"text":121,"@type":113},"CLDN18.2 positivity is associated with patient prognosis and a characteristic TME, and therapeutic strategies targeting CLDN18.2 are supported by preclinical data and clinical trial results, including improvements in survival outcomes with zolbetuximab in relevant patient groups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355826,1790171640,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Xie etal. Journal of Hematology & Oncology (2026) 19:37 [https://doi.org/10.1186/s13045-026-01803-9](https://doi.org/10.1186/s13045-026-01803-9)  \nJournal of Hematology & Oncology  \nREVIEW Open Access  \nClaudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies  \nYi Xie1†, Pengfei Guan1†, Dan Liu1, Zhi Peng1, Xiaotian Zhang1, Lin Shen1* and Yang Chen1,2*  \nAbstract  \nClaudin18 .2 (CLDN18 . 2) is primarily expressed in gastric epithelial cells, where it plays a crucial role in maintaining the integrity of the gastric mucosal barrier. Its aberrant expression is closely associated with the initiation, progression, and tumor microenvironment (TME) remodeling of gastric cancer(GC) . Clinical evidence indicates that CLDN18 .2 is highly expressed in a substantial proportion of GC. Notably, its expression appears to be  \nlargely independent of established biomarkers such as human epidermal growth factor receptor 2 (HER2) and programmed death-ligand 1 (PD-L1) . These features collectively suggest CLDN18 .2 as a viable candidate for therapeutic intervention in GC. Increasing evidence suggests that CLDN18 .2 positivity is associated with patient prognosis and may indicate a distinctive TME characterized by increased infiltration of CD4⁺ and CD8⁺ T cells, macrophages, and cancer-associated fibroblasts. This review systematically summarizes the biological characteristics of CLDN18 .2 and the features of CLDN18 . 2-positive TME, and provides an overview of emerging therapeutic strategies targeting CLDN18 .2. The aim is to elucidate the biological and clinical significance of CLDN18 .2 in GC and to provide insights for optimizing future precision therapies.  \nKeywords Claudin18 . 2, Gastric cancer, Tumor microenvironment, Clinical biomarkers  \n†Yi Xie and Pengfei Guan contributed equally to this work.  \n*Correspondence: Lin Shen [shenlin@bjmu.edu.cn](shenlin@bjmu.edu.cn)[ ](shenlin@bjmu.edu.cn)Yang Chen [Yang_chen@bjcancer.org](Yang_chen@bjcancer.org)  \n1Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, Beijing 100142, China 2Department of Gastrointestinal Cancer, Beijing GoBroad Hospital, Beijing 102200, China  \nBackground  \nGastric cancer (GC) is a highly heterogeneous and biologically complex malignancy. As of 2023, it remains the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related mortality worldwide [1]. Owing to its insidious onset and lack of specific symptoms at early stages, the majority of patients present with locally advanced or metastatic disease at diagnosis, contributing to the overall poor prognosis [2]. Conventional systemic chemotherapies—such as capecitabine plus oxaliplatin (CAPOX), S-1 plus oxaliplatin (SOX), and leucovorin, 5-FU plus oxaliplatin (FOLFOX)—provide only modest clinical benefit [3, 4]. More recently, combinations incorporating human epidermal growth factor receptor 2 (HER2)-targeted agents, vascular endothelial growth factor-directed therapies, or programmed  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceed","cbCaihEtXQyb8jCn","https://ap.wps.com/l/cbCaihEtXQyb8jCn","pdf",2537678,25,"English","# Abstract\n## Claudin18.2 in gastric cancer\n## Tumor microenvironment features\n## Emerging therapeutic strategies","[{\"question\":\"What role does Claudin18.2 play in the gastric mucosal barrier?\",\"answer\":\"Claudin18.2 is primarily expressed in gastric epithelial cells and contributes crucially to maintaining the integrity of the gastric mucosal barrier.\"},{\"question\":\"How is Claudin18.2 expression related to established biomarkers like HER2 and PD-L1?\",\"answer\":\"CLDN18.2 expression is described as largely independent of established biomarkers such as HER2 and PD-L1, suggesting it can provide distinct clinical information.\"},{\"question\":\"Why is Claudin18.2 considered a therapeutic target in gastric cancer?\",\"answer\":\"CLDN18.2 positivity is associated with patient prognosis and a characteristic TME, and therapeutic strategies targeting CLDN18.2 are supported by preclinical data and clinical trial results, including improvements in survival outcomes with zolbetuximab in relevant patient groups.\"}]","Claudin18.2 positive gastric cancer - biology, tumor microenvironment, and therapeutic strategies | PDF",1790121226,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f0049b07597b42f887b85f4d27cfc8f.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e51ac6b9bd06e5c87935e0cd1cef545.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14333a12cfef198fac2ac922e7a62edf.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2427a6d47f0a39a8a7884ff96d16da29.webp",980,1306]